Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses
Helen Tremlett(St. Michael's Hospital), Anne‐Louise Ponsonby(Royal Children's Hospital), Fotini Pittas(University of Tasmania), Leigh Blizzard(University of Tasmania), Bruce Taylor(University of London), Ingrid van der Mei(University of Tasmania), Terence Dwyer(The University of Melbourne), Glenys Paley(Menzies School of Health Research)
Cited by 78
Related Papers
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Childhood Adiposity, Adult Adiposity, and Cardiovascular Risk Factors
|New England Journal of Medicine|2011|1.6k
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
|Neurology|2014|1.3k
Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants
|Journal of Allergy and Clinical Immunology|2011|1k
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624